aTyr Pharma, Inc. (ATYR) has a negative trailing P/E of -1.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 1.4 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -97.98%, forward earnings yield 73.53%. PEG 0.01 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 40/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -0.1 | 0.00 | 0.05 | 0.00 | - |
| 2017 | -0.1 | 0.00 | 0.05 | 0.00 | - |
| 2018 | -0.1 | 0.00 | 0.11 | 0.00 | - |
| 2019 | -0.2 | 0.00 | 0.27 | 13.76 | - |
| 2020 | -1.0 | 0.01 | 0.50 | 1.52 | - |
| 2021 | -1.0 | 0.00 | 0.30 | 0.00 | - |
| 2022 | -1.1 | 0.11 | 0.69 | 4.73 | - |
| 2023 | -1.8 | 0.04 | 1.02 | 262.72 | - |
| 2024 | -4.2 | 0.49 | 3.84 | 1,143.94 | - |
| 2025 | -1.0 | 0.14 | 1.08 | 383.25 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-34.20 | $0.00 | $-57.86M | - |
| 2017 | $-26.16 | $0.00 | $-48.21M | - |
| 2018 | $-16.13 | $0.00 | $-34.52M | - |
| 2019 | $-7.03 | $422K | $-23.6M | -5593.1% |
| 2020 | $-1.77 | $10.46M | $-16.22M | -155.2% |
| 2021 | $-1.77 | $0.00 | $-33.77M | - |
| 2022 | $-1.60 | $10.39M | $-45.34M | -436.5% |
| 2023 | $-0.94 | $353K | $-50.39M | -14274.5% |
| 2024 | $-0.86 | $235K | $-64.02M | -27243.8% |
| 2025 | $-0.80 | $190K | $-74.12M | -39009.5% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.59 | $-0.71 – $-0.39 | $3.86M | $3.86M – $3.86M | 6 |
| 2027 | $-0.41 | $-0.70 – $-0.12 | $8.79M | $8.79M – $8.79M | 6 |
| 2028 | $-0.20 | $-0.59 – $1.02 | $40.27M | $40.27M – $40.27M | 8 |
| 2029 | $0.62 | $0.62 – $0.62 | $155.96M | $155.96M – $155.96M | 6 |
| 2030 | $1.46 | $1.46 – $1.46 | $312.99M | $312.99M – $312.99M | 6 |
